Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up

• Martin Dreyling,
• Andre Goy,
• Georg Hess,
• Brad S. Kahl,
• José-Ángel Hernández-Rivas,
• Natasha Schuier,
• Keqin Qi,
• Sanjay Deshpande,
• Angeline Zhu,
• Lori Parisi,
• Michael L. Wang

Affiliations

Martin Dreyling

1 Department of Medicine III, University Hospital, Ludwig Maximilians University, Munich, Germany

Andre Goy

2 Department of Hematology & Oncology, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, USA

Georg Hess

3 Department of Hematology, Oncology and Pneumology, University Medical School of the Johannes Gutenberg-University, Mainz, Germany

Brad S. Kahl

4 Department of Medicine, Washington University, St Louis, Missouri, USA

José-Ángel Hernández-Rivas

5 Department of Hematology, Infanta Leonor University Hospital, Complutense University, Madrid, Spain

Natasha Schuier

6 Janssen Research & Development, Neuss, Germany

Keqin Qi

7 Clinical Biostatistics, Janssen Research & Development, Titusville, New Jersey, USA

Sanjay Deshpande

8 Global Medical Affairs, Janssen Global Services LLC, Raritan, New Jersey, USA

Angeline Zhu

8 Global Medical Affairs, Janssen Global Services LLC, Raritan, New Jersey, USA

Lori Parisi

8 Global Medical Affairs, Janssen Global Services LLC, Raritan, New Jersey, USA

Michael L. Wang

9 Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas, USA